EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY

被引：0
|
作者：
Chen, Bowen [1 ]
Zhang, Linzhi [2 ,3 ]
Cheng, Jiamin, Sr. [2 ]
Yan, Tao [2 ]
Lu, Yinying [1 ]
机构：
[1] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1045
引用
收藏
页码：637A / 638A
页数：2
相关论文
共 50 条
  • [41] The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
    Yang, Zeran
    Chen, Guang
    Cui, Ye
    Xiao, Guowen
    Su, Tianhao
    Yu, Jianan
    Zhang, Zhiyuan
    Han, Yanjing
    Yang, Kailan
    Jin, Long
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 321 - 327
  • [42] The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Tyrosine kinase inhibitors vs anti-VEGF antibody, combined with anti-PD-1 inhibitors and TACE in the conversion therapy for hepatocellular carcinoma: A retrospective multicenter real-world study
    Ling, Q.
    Jiang, H.
    Sheng, L.
    Zhang, Y.
    Wang, B.
    Mu, A.
    Zhu, Y.
    Zheng, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S670 - S670
  • [44] Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study
    Palmer, Mathias E.
    Gile, Jennifer J.
    Storandt, Michael H.
    Jin, Zhaohui
    Zemla, Tyler J.
    Tran, Nguyen H.
    Mahipal, Amit
    CANCERS, 2023, 15 (19)
  • [45] Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
    Miyamoto, Satoshi
    Tsukaguchi, Akihiro
    Kuhara, Hanako
    Otsuki, Taiichiro
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Nishino, Kazumi
    Takeda, Yoshito
    Kijima, Takashi
    Okumura, Meinoshin
    Kumanogoh, Atsushi
    Mori, Masahide
    THORACIC CANCER, 2025, 16 (06)
  • [46] The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study
    Song, Danjun
    Hao, Weiyuan
    Cao, Fei
    Luo, Jun
    Guo, Liwen
    Zhang, Zhewei
    Zheng, Jiaping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Effects of combination therapy using lenvatinib and anti-pd-1 antibody on liver function in patients with advanced hepatocellar carcinoma
    Shen, Y.
    Sun, H.
    Huang, C.
    Zhu, X.
    Xu, M.
    Tan, C.
    Liang, F.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S691 - S691
  • [48] Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma
    Liu, Bao-Jiang
    Gao, Song
    Zhu, Xu
    Guo, Jian-Hai
    Kou, Fu-Xin
    Liu, Shao-Xing
    Zhang, Xin
    Wang, Xiao-Dong
    Cao, Guang
    Chen, Hui
    Liu, Peng
    Xu, Hai-Feng
    Gao, Qin-Zong
    Yang, Ren-Jie
    IMMUNOTHERAPY, 2021, 13 (17) : 1395 - 1405
  • [49] Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
    Zhang, Weihao
    Zhang, Kai
    Liu, Changfu
    Gao, Wei
    Si, Tongguo
    Zou, Qiang
    Guo, Zhi
    Yang, Xueling
    Li, Mei
    Liu, Dongming
    Mu, Han
    Li, Huikai
    Yu, Haipeng
    Xing, Wenge
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
    Kobayashi, Kazufumi
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Moriguchi, Michihisa
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Kanogawa, Naoya
    Shiko, Yuki
    Inaba, Yosuke
    Nakamura, Kazuyoshi
    Azemoto, Ryosaku
    Ito, Kenji
    Okabe, Shinichiro
    Atsukawa, Masanori
    Itobayashi, Ei
    Ikeda, Masafumi
    Morimoto, Naoki
    Itoh, Yoshito
    Kato, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 512 - 512
12345